Table 2.
Improvement in PAP in patients with sarcoidosis-associated pulmonary hypertension following bosentan treatment
| Patient | Initial mean PAP (mmHg) | Follow-up mean PAP (mmHg) | Pulmonary hypertension therapy | Other sarcoidosis medications |
| 1 | 73 | 41 | Epoprostenol | Prednisone, methotrexate, azathioprine, infliximab |
| 2a | 63 | 45 | Bosentan | Prednisone |
| 3a | 61 | ND | Bosentan, epoprostenol | Prednisone, azathioprine |
| 4 | 53 | 23 | Amlodipine | Prednisone, methotrexate |
| 5 | 50 | ND | Bosentan | Prednisone, methotrexate |
| 6 | 38 | 36 | Bosentan | Prednisone, methotrexate, azathioprine |
| 7 | 36 | 24 | Bosentan | Prednisone, methotrexate, infliximab |
Shown are data demonstrating improvement in pulmonary artery pressure (PAP) following addition of bosentan to standard anti-inflammatory therapy in a small cohort of patients with sarcoidosis-associated pulmonary hypertension. aPatient died. ND, not determined.